Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ...
Despite significant development in the pharmacological treatment of inflammatory bowel diseases (IBD...
International audienceBackgroundPatients with Crohn's disease are increasingly receiving antitumour ...
Debate exists concerning the presumed risk of postoperative complications in patients with ulcerativ...
Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory ...
International audienceBackground While the effect of anti-TNFs on postoperative outcomes in patients...
Background/Aims: Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn\u27s di...
Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated effi...
The rate of abdominal surgical interventions and associated postoperative complications in inflammat...
International audienceBackground and aims: About one-third of inflammatory bowel disease (IBD) patie...
PURPOSE: The impact of preoperative use of TNF-alpha inhibitors on postoperative complications i...
The real impact of biological therapy (anti-TNF agents) in abdominal operations secondary to Crohn's...
AbstractBackground and aimsAbout one-third of inflammatory bowel disease (IBD) patients still requir...
Despite significant development in the pharmacological treatment of inflammatory bowel diseases (IBD...
International audienceBackgroundPatients with Crohn's disease are increasingly receiving antitumour ...
Debate exists concerning the presumed risk of postoperative complications in patients with ulcerativ...
Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory ...
International audienceBackground While the effect of anti-TNFs on postoperative outcomes in patients...
Background/Aims: Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn\u27s di...
Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated effi...
The rate of abdominal surgical interventions and associated postoperative complications in inflammat...
International audienceBackground and aims: About one-third of inflammatory bowel disease (IBD) patie...
PURPOSE: The impact of preoperative use of TNF-alpha inhibitors on postoperative complications i...
The real impact of biological therapy (anti-TNF agents) in abdominal operations secondary to Crohn's...
AbstractBackground and aimsAbout one-third of inflammatory bowel disease (IBD) patients still requir...
Despite significant development in the pharmacological treatment of inflammatory bowel diseases (IBD...
International audienceBackgroundPatients with Crohn's disease are increasingly receiving antitumour ...
Debate exists concerning the presumed risk of postoperative complications in patients with ulcerativ...